BPC-157 (Body Protection Compound-157): preparation and storage
Intended for research use only. Not a medicinal product.
Contents (6 sections)
BPC-157: what “stable peptide” means
BPC-157 is a synthetic pentadecapeptide with sequence GEPPPGKPADDAGLV. The literature’s description “stable gastric pentadecapeptide” refers to a particular research context. It does not guarantee room-temperature stability of every solution, sterility or unchanged activity after repeated opening. Molar conversion requires the documented chemical form; accurate quantitative work also requires peptide content, water and counterion information.
In migration and wound-closure assays, initial density and proliferation must be controlled to interpret scratch closure. Faster closure does not demonstrate migration alone if cells also divide. Retain a vehicle control and a baseline image of each well. Do not combine BPC-157 with another peptide in a stock intended to measure one component. Combination experiments need each separate component and the mixture at comparable component concentrations.
Quantitative stocks benefit from recovery measurements after contact with vessels and filters. Incomplete dissolution and adsorption can produce the same concentration error but require different investigations. Removing precipitate does not justify continuing to calculate concentration from the original mass divided by volume. For prolonged incubations, check intact BPC-157 in the actual medium rather than relying on fresh-powder purity. Tissue-healing findings do not replace stock analytical control.
Two studies with different cellular responses
Chang and colleagues studied tendon explants and rat Achilles-tendon fibroblasts. Endpoints included explant outgrowth, transwell migration, spreading, survival under H2O2 stress, F-actin and FAK/paxillin phosphorylation. BPC-157 did not directly increase MTT-assessed proliferation in that model, although other endpoints changed. “The peptide stimulates cell growth” is therefore unsuitable as a universal description or the sole stock-acceptance criterion.
Huang and colleagues used a rat alkali-burn model and separate experiments in human umbilical-vein endothelial cells, HUVECs. They measured proliferation, migration, tube formation and VEGF/ERK signalling. This differs from tendon fibroblasts. Different proliferation responses between the studies do not automatically indicate contradictory evidence or different reagent quality; cell type, method and timing must be considered first.
Preparation for migration and angiogenesis assays
For scratch assays image every well at baseline and standardise scratch width. Comparing final areas alone ignores different starting defects. Assess proliferation independently when studying migration. For transwells record membrane pores and both chamber compositions; a serum gradient itself stimulates migration. Dilute the BPC-157 stock so that vehicle or added salts do not create an additional chamber gradient.
In tube-formation assays matrix composition and lot affect network formation, so do not change them simultaneously with the stock. Reagent-only wells are useful when matrix affects optical or colorimetric measurements. A phosphorylation change does not quantify BPC-157 itself. Chemical stability in medium requires a method distinguishing intact peptide from transformation products rather than a total-protein signal.
Mass concentration and pilot dissolution
Illustrative arithmetic: 5 mg in a final 2.50 mL gives 2 mg/mL. To make 4 mL at 0.005 mg/mL, use 10 µL stock and medium to 4 mL. Use an intermediate dilution if smaller transfers would fall outside the pipette’s reliable range. These numbers demonstrate mass balance rather than a published exposure or recommended method. In a blend they do not establish BPC-157 content without its component mass.
An aqueous stock first requires verified solubility of the supplied form. The sequence contains acidic and basic residues, but charge counting only informs a pilot trial; it does not guarantee solubility at any pH. If no solvent is specified, examine a small separate sample. “Gastric” in the name is not justification for adding acid or base to the entire vial.
What to assess during storage
Does a review of stable BPC-157 establish your solution lifetime? No: its name and biological review do not measure your buffer, vessel and temperature. Can precipitate simply be removed? Nominal concentration is then unverified and analyte recovery must be measured. Should preservative be added? Only when compatible with the method and specification, because it may change cell responses. Preservative does not establish sterility or absence of endotoxin.
Keep dry reserve under labelled conditions separately from dilute working samples. If solution freezing is permitted, prepare single-experiment aliquots and record thaw cycles. Compare days using the same reference stock and cell system. Differences between HUVEC and fibroblast migration are not a storage test: they change the biological model and must be separated from changes in peptide quality.
For FAK or ERK analysis specify whether the measurement concerns phosphorylated protein, total protein or their ratio. The tendon-cell study distinguished activation from total protein abundance. Normalising only by lysate volume may obscure cell-number differences. This concerns biological sample preparation separately from BPC-157 stock concentration.
End of article
BPC-157
for laboratory research
Packs and current prices on the product page.